Skip to content
thestock.space

Strides Pharma Science (STAR) had a P/E of 14.9× on 6 Nov 2026, below the industry P/E of 28.7×, and the shares are 21% below their 52-week high. It earns ROCE of 20% and ROE of 20%, and sales grew 8.7% a year over 3 years. Its dividend yield is 0.5%, and debt is 0.55× equity. It is a small-cap company with a market cap of ₹9,214 Cr, ranked 35th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 4.7% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year
Open
₹1,002.60
Day high
₹1,009.00
Day low
₹991.80
Prev. close
₹1,007.60
Volume
1.9 L

Health check

3 good · 1 fair · 2 to check
  • ReturnsBehind

    +4.7% over a year, better than 1 of 7 peers.

  • Price tagCheaper

    P/E 14.9 vs industry 28.7.

  • GrowthSlow

    Sales +8.7% a year over 3 years.

  • ProfitabilityStrong

    ROCE 20.3% vs peer median 17.9%.

  • Balance sheetFair

    Debt 0.55× equity, interest covered 5.5×.

  • Red flagsNone found

    No warning signs in the headline numbers.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹9,214 Cr, #35 of 154 in its industry by size.

Defensive

Beta 0.36 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Sep 2026: sales ₹5,213 Cr · profit ₹617 Cr
Market cap
₹9,214 Cr
Small cap
P/E
14.9
Industry 28.7
Price to book
2.70
Peers 4.99
Dividend yield
0.50%
ROE
20.3%
Peers 14.7%
ROCE
20.3%
Peers 17.9%
Debt to equity
0.55
Debt ₹1,905 Cr
EPS (TTM)
₹66.91
Face value ₹10
OPM (TTM)
18.3%
Net margin 11.8%
Sales growth
+17.1%
Latest quarter vs a year ago
Profit growth
+2.5%
Latest quarter vs a year ago
Price to sales
1.77
EV/EBITDA 13.0

Strengths and risks

Strengths

  • Return on equity of 20.3%.
  • Return on capital employed of 20.3%.
  • Quarterly sales up 17.1% on a year ago.
  • P/E of 14.9 against an industry P/E of 28.7.
  • Positive operating cash flow in each of the last 4 years.

No obvious red flags in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About Strides Pharma Science

Strides Pharma Science Limited, a pharmaceutical company, engages in the development, manufacturing, and marketing of pharmaceutical products in North America, Australia, Africa, Europe, India, the rest of Asia, and internationally. The company offers generic finished dosage formulations in a range of dosages, such as tablets, hard capsules, sachets, liquids, nasal sprays, topical formulations, and controlled substances; and therapeutic products,…

Headquarters
Bengaluru
Employees
3,535
Sector
Healthcare
ISIN
INE939A01011
Website
strides.com

Price range

52 weeks

₹768.65₹1,260.90

Today

₹991.80₹1,009.00
Avg volume (3M)
4.2 L
1-year return
plus 4.7%
From 52-week high
minus 20.7%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
STARStrides Pharma Science999.60minus 0.79%9,21414.92.70–20.3%18.3%––0.50%plus 4.7%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.58%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Dec 25Mar 26Jun 26Sep 26
1,1201,1951,3231,2651,430
9029591,0841,0361,179
218236240230251
19.5%19.8%18.1%18.2%17.5%
8.71079.63.65
47.543.441.640.646.5
48.950.653.256.457.2
−8.4−3.3−6.463.2−1.7
122245148200150
13.5%15.2%12.7%17.1%10.8%
99.6202127157131
10.8121.9213.7717.0214.19

Sep 25 not reported by the data source.

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+8.7%
ROE
20.3%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
3,6083,7304,3924,628
–+3.4%+17.7%+5.4%
3,4333,3863,6203,809
175344772819
4.8%9.2%17.6%17.7%
12.915718.4195
218239207150
243221192202
−12.9−15796.46.7
−286−115487669
19.3%−25.4%15.9%14.1%
−203−70.63,593556
-22.49-7.76390.5060.34

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
90.391.992.292.2
2,1222,0342,4603,015
3,0302,5171,8801,758
1,3971,1971,6172,062
6,6385,8406,0496,927
1,3929771,0181,183
67.898.6138191
56.212.2339296
361290199204
4,7624,4624,3545,053
6,6385,8406,0496,927

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
44.4701684703
302−150−89.7−173
−214−693−643−453
133−143−47.976.1
−94.9−118−247−418
−50.5583437285
–−13.5−23−36.9

Shareholding pattern

Source: NSE filings
29.0%
promoters
  • Promoters29.00%
  • Public71.00%
  • As of 30 Sep 2026
QuarterSplitPromotersPublicPromoter change
30 Sep 202629.00%71.00%plus 1.09
30 Jun 202627.91%72.09%0.00
31 Mar 202627.91%72.09%plus 0.05
31 Dec 202527.86%72.14%0.00
30 Sep 202527.86%72.14%–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you